The potential for selection in vitro of Legionella pneumophila mutants resistant to fluoroquinolones was investigated. Six distinct clinical isolates of L. pneumophila were subcultured in subinhibitory concentrations of ciprofloxacin, levofloxacin, clinafloxacin, trovafloxacin and moxifloxacin until MICs increased at least eight-fold. The numbers of serial passages required in microbroth dilution series were determined. The gyrA gene of the six parental strains, and 12 selected mutant strains, was sequenced. The five quinolones differed markedly in their ability to select mutants with decreased susceptibility. The average number of serial passages required was low in the cases of clinafloxacin (n = 10.6), ciprofloxacin and levofloxacin (both n = 13), but notably higher for trovafloxacin (n = 26.6) and moxifloxacin (n = 22.5). Five mutants treated with ciprofloxacin and three treated with moxifloxacin showed Thr83→Lys or Thr83→Ile amino acid changes in the gyrA gene. In conclusion, different quinolones lose their antimicrobial effect after a varying number of passages. This study demonstrated, for the first time to our knowledge, that gyrA in L. pneumophila is a possible target of fluoroquinolones.
Introduction
Fluoroquinolones have become an important alternative to macrolide antibiotics in the treatment of legionnaires' disease, although considerable mutation frequencies in vitro of Legionella pneumophila in the presence of ciprofloxacin and rifampicin have been reported. 1 New fluoroquinolones have been developed to obtain a broad spectrum of antimicrobial activity. This includes activity against Gram-positive pathogens causing respiratory tract infections. These new drugs vary in their ability to induce the development of mutant resistant strains. For instance, C-8-methoxyl fluoroquinolones require two mutations for expression of resistance. 2 Moreover, they may differ in their primary target structures, which may be the subunits of the gyrase, topoisomerase IV or efflux pumps.
Induction of resistance upon exposure to quinolones has been described for many bacterial species. In contrast to legionellae, most nosocomial pathogens are transmitted horizontally between persons, which facilitates a stepwise accumulation of mutations and increases the MIC to clinical ineffectiveness. However, pathogens can become resistant during the course of a patient's therapy. The likelihood of this occurring varies between antibiotics. 3 According to anecdotal reports, subjects with legionnaires' disease may respond only after a change in antimicrobial therapy. 4, 5 One possible explanation for this phenomenon could be the loss of susceptibility during antimicrobial treatment. However, susceptibility data were not presented in these case reports.
The objectives of this study were: (i) to determine how effective new fluoroquinolones are at inducing a stable increase in MICs-this was conducted by serial passages on media containing subinhibitory concentrations of the antibiotic; (ii) to demonstrate whether there are differences in the number of passages required for each fluoroquinolone; and (iii) to search for resistance mechanisms, i.e. to investigate the quinolone resistance-determining region (QRDR) of the gyrA gene for amino acid changes.
Materials and methods

Antimicrobial agents
Trovafloxacin (Pfizer, Karlsruhe, Germany), moxifloxacin and ciprofloxacin (Bayer Vital, Wuppertal, Germany), levofloxacin (Aventis Pharma, Bad Soden, Germany), clinafloxacin (Gödecke Parke-Davis, Freiburg, Germany) and gentamicin (Merck, Darmstadt, Germany) were laboratory reference standard substances. All agents were prepared according to the manufacturers' recommendations.
Bacterial strains
Six clinical isolates of L. pneumophila were obtained from bronchoalveolar lavages of patients with legionnaires' disease. The isolates were identified by standard microbiological methods and PCR. 6 All belonged to serogroup 1, with the exception of strain no. 5, which belonged to serogoup 8. (Serogroup data were kindly provided by Dr H.-G. Meyer, Institute of Medical Microbiology and Hygiene, University of Mainz, Mainz, Germany.) Selected strains represented five different genotypes and were determined by means of arbitrarily primed PCR (AP-PCR data not shown). 7 After five passages on buffered charcoal yeast extract α-ketoglutarate (BCYEα) agar (Heipha, Heidelberg, Germany), the isolates were stored in aliquots of BYEα broth-glycerol (1:1) at -70°C. BYEα broth contained 0.9% (w/v) yeast extract (Difco, Augsburg, Germany) and 10% (v/v) legionella -buffered charcoal yeast extract (BCYE) -Supplement SR 110A (Oxoid Unipath, Wesel, Germany) adjusted to pH 6.9 at a final volume of 100 mL. For the performance of the experiments, an aliquot was thawed and grown on BCYEα agar in 5% CO 2 at 37°C for 4 days.
MIC determinations
Antimicrobial susceptibilities were determined by microdilution susceptibility testing in BYEα broth, as described previously. 8, 9 Each experiment was performed in duplicate. Bacteria were added, at a final concentration of 5 × 10 4 cfu per 100 µL, to geometric dilution series of the antimicrobial agent. After incubation of the dilution series for 48 h at 37°C, MICs of bacterial growth were read visually.
Serial passages
Passages were performed three times a week by taking an inoculum from the well with the next concentration below the MIC. Wells of the geometric dilution series with the highest antimicrobial concentrations showing growth (i.e. 1/2 × MIC) contained 2-7 × 10 6 cfu. Following a 100-fold dilution of these well contents, bacteria were inoculated into a fresh microbroth dilution series. Serial passages were performed until the MIC of a strain had increased at least eight-fold. Subsequently, resistant strains were passaged ten times on antibiotic-free BCYEα agar.
The stability of the resistant phenotype, and the crossresistance between the fluoroquinolones, were then determined by microdilution susceptibility testing.
Typing by AP-PCR
Three to five colonies from a freshly grown culture were resuspended in 100 µL of TE (10 mM Tris-HCl pH 8.0, 0.1 mM EDTA) in a microfuge tube and incubated for 15 min at 95°C. After chilling on ice, bacterial debris was pelleted by centrifugation at 15 000g for 20 s. The supernatant was transferred to a fresh microfuge tube.
The AP-PCR was performed as described previously. 7 The M13 primer (5′-TTATGTAAAACGACGGCCAGT-3′) used for typing was fluorescently labelled with Cy-5 during manufacture (Amersham Pharmacia Biotech, Germany). PCR was performed in a total volume of 25 µL, with 1 µL of the bacterial lysate being added to a PCR mix comprising 10 mM Tris-HCl pH 9.0, 3 mM MgCl 2 , 50 mM KCl, 0.2 mM dNTPs (Amersham Pharmacia Biotech), 1.25 U Taq DNA polymerase (Boehringer Mannheim). The PCR comprised 45 cycles of 60 s at 94°C, 60 s at 36°C, 120 s at 72°C and a final extension step at 72°C for 2 min. PCR products were detected by analysis of a 1.2 µL portion on an ALF Express DNA Sequencer (Pharmacia) as described previously. 10 Fingerprints of the parental and mutant strains were analysed visually in the range 120-1000 nucleotides.
Sequencing of the gyrA gene
PCR analysis was performed on crude DNA, prepared as described above. Amplification was achieved with consensus primers for the Legionella gyrA gene p39 [5′-GATGG(C/T)-TTAAAGCC(C/T)GT(G/T)CAT] and p179 rev [5′-CGC-CAT(A/C)CCTACAGC(G/T)AT(A/C)CC-3′], which comprised codons 39-179, according to the Escherichia coli numbering. 11 PCR fragments were isolated by use of High Pure PCR Product Purification Kit (Roche Diagnostics GmbH, Mannheim, Germany). DNA sequencing reactions were performed at MWG (MWG Biotech; Ebersberg, Germany) in forward and reverse directions, using the primers p39 and p179rev. Both strands were sequenced as a cross-check. 
Statistical analysis
For analysis of the fluoroquinolones and their different propensities to cause resistance, the outcome 'number of passages' was considered. The number of passages are ordinal data. Since all pairwise comparisons of the five different types of compounds were of interest, the multiple two-way rank procedure by Wilcoxon and Wilcox was used. 12 The two-way analysis takes into account that bacteria from the same six strains were studied for each of the five antimicrobials. Comparisons were two-sided and at the 5% level.
Results
Subculturing of all six strains in subinhibitory concentrations of all five quinolones raised the MIC at least eight-fold after a maximum of 30 passages ( Table 1 There was an interesting dichotomy between the numbers of required passages in the presence of moxifloxacin and trovafloxacin versus ciprofloxacin, levofloxacin and clinafloxacin. The mean numbers of passages (n) from the experiments with all six strains were lowest with clinafloxacin (n = 10.6), ciprofloxacin (n = 13) and levofloxacin (n = 13). In contrast, moxifloxacin and trovafloxacin induced resistance only after a higher average number of passages (n = 22.5 and 26.6). Pairwise comparison, by means of the multiple twotailed Wilcoxon and Wilcox test, revealed statistically significant differences (P ≤ 0.05) between moxifloxacin and clinafloxacin, as well as trovafloxacin compared with levofloxacin and clinafloxacin.
After 10 antibiotic-free passages, MICs for the mutant strains remained stably increased by at least two doubling dilutions. Clear cross-resistance between all five antimicrobials was observed.
It was confirmed that all resistant strains were derived from their parental strains. Typing the strains by means of AP-PCR revealed five different genotypes. Strains 4 and 6 belonged to the same genotype, as confirmed by macrorestriction analysis (data not shown). The DNA fingerprints of all mutant strains were indistinguishable from their parental strains.
In a tentative explanation of the resistance mechanisms, the DNA sequences of the gyrA gene were investigated. 13 Sequencing of the QRDR disclosed non-silent nucleotide changes in five of six, and half of the strains subcultured in the presence of ciprofloxacin and moxifloxacin, respectively ( Table 2 ). All changes occurred at codon position 83, which uniformly coded for threonine in all six parent strains. Four of the 12 investigated mutant strains did not disclose any gyrA changes.
Discussion
Despite appropriate treatment of legionnaires' disease with intracellularly acting antimicrobials, fatality rates can remain as high as 50%. 14 Generally, this is ascribed to severity of illness and underlying diseases. Based on early studies, erythromycin is considered to be the first line therapy. 15, 16 An early report showed the ease with which erythromycin-resistant strains were obtained in vitro, which raises the possibility of selecting resistant strains during patient therapy. 1, 17 Fluoroquinolones are another promising class of antimicrobial for treatment of pneumonia. Since their introduction, they have been increasingly discussed as an alternative in the therapy of legionnaires' disease. These drugs are known to induce drug resistance, which spreads through the community, mainly by horizontal transfer. In the presence of rifampicin and ciprofloxacin, mutation frequencies for Legionella have been reported in the range of 1-4 × 10 -8 to 10 -8 ->10 -7 . 1 The present study compares the propensity of ciprofloxacin and other new fluoroquinolones to induce resistance, and gives a tentative explanation about the mechanism.
Even when a smaller number of bacterial counts are subcultured, employing the microbroth dilution technique, fluoroquinolones are able rapidly to induce a stable, decreased susceptibility within fewer than 10 passages. Since every 100 µL subculture at 1/2 × MIC ended in 2-7 × 10 6 cfu, in total <10 8 cfu had been exposed to subinhibitory concentrations; two orders of magnitude less than can be expected in human infections. [18] [19] [20] In contrast to results in vitro, animal experiments showed no evidence of rifampicin-induced resistance to L. pneumophila; 21 however, it should be acknowledged that the bacterial burden can vary in vivo.
The clinical importance of these study findings might be questioned, since legionellae are not transmitted horizontally. Therefore, clinical isolates with diminished susceptibility imply development of resistance de novo. However, case reports in the literature about initial treatment failures show that final cures were achieved after changing the antimicrobial class in the treatment regimen. 4, 5, 22, 23 Unfortunately, few of the reports indicated the susceptibility of the strains before and after the initial treatment regimen. 22, 23 Although this has not been documented for legionnaires' disease, that pathogens can become resistant during the course of a patient's antimicrobial therapy is unequivocal. 3 The five quinolones investigated differed with respect to their propensity to induce resistance in a dichotomous manner. For ciprofloxacin, levofloxacin and clinafloxacin this potential was markedly higher than for moxifloxacin and trovafloxacin. Presumably, the replacement of the (C-8) carbon with nitrogen (trovafloxacin) or the addition of a methoxy substituent to C-8 (moxifloxacin) decreases the probability of emerging resistances. 24 The low propensity of moxifloxacin to induce resistant mutants has been well documented for other species. 2, 25 There are limited published data on the mechanisms of antimicrobial resistance in Legionella. [26] [27] [28] Most investigations address the intracellular localization of replicating strains. Furthermore, antimicrobial susceptibility itself seems to depend on the state of growth. 27, 28 In this study, the QRDR of the gyrA gene was investigated in the search for primary fluoroquinolone targets and resistance mechanisms in L. pneumophila. For this purpose, mutants were chosen from antimicrobial groups with varying activity, which had been rendered resistant in the presence of ciprofloxacin and moxifloxacin. In numerous Gram-negative bacteria, gyrase A has been demonstrated as the primary target structure of most fluoroquinolones. 29 To our knowledge, this is the first study to describe amino acid changes at gyrA codon position 83 of L. pneumophila, as found in other fluoroquinolone-resistant species (for review see ref. 30). This residue is assumed to be involved in the drug binding. 31 Mutants such as Thr83→Ile have been found in Pseudomonas aeruginosa, Klebsiella oxytoca, Citrobacter freundii and Enterobacter aerogenes. 29 There is little doubt that the increased resistance against all five fluoroquinolones is caused by these gyrA mutants, even if a reversion of the resistant phenotype by complementation with the wild-type gene has not been performed. But the fact that four of the 12 mutants, appearing in the presence of ciprofloxacin and moxifloxacin, did not display changes in the QRDR of gyrA is highly indicative of additional target structures and resistance mechanisms in Legionella, such as topoisomerase IV, or multi-drug efflux pumps. Detailed investigation of these mechanisms would have been beyond the scope of this study.
In conclusion, this work confirms that multiple sub-MIC passages of L. pneumophila can produce quinolone antimicrobial resistant mutants. However, the potency to evoke such changes seems to differ markedly in different fluoroquinolones. This is the first study to demonstrate that reduced fluoroquinolone susceptibility in L. pneumophila can be associated with gyrA mutations.
